The “hallmarks of cancer” proposed by Hanahan and Weinberg [20, 21]

Slides:

Advertisements

Similar presentations

Kaplan–Meier survival curves of interstitial pneumonia with autoimmune features (IPAF) with usual interstitial pneumonia (UIP) pattern (on high-resolution.

Advertisements

Physiological changes in pulmonary arterial hypertension (PAH) patients which occur in response to pregnancy. Physiological changes in pulmonary arterial.

a) Normal parasternal long-axis view.

In chronic haemorrhage a) several pigmented macrophages fill the alveoli with dense fibrosis of the interstitium; b) the haemosiderin pigment in macrophages.

A 45-year-old with pulmonary hypertension

The effect of sequential addition of sildenafil to first-line epoprostenol on exercise capacity measured using 6-min walk distance (6MWD) in the PACES.

Flowchart showing the requirement for starting, documenting and evaluating the effect on quality of life (QoL) of interdisciplinary best supportive care.

Familial history of hereditary haemorrhagic telangiectasis (HHT) of the 29-yr-old patient (•) with HHT and severe pulmonary arterial hypertension (PAH).

Plexiform lesion from a patient with severe pulmonary hypertension demonstrating the exuberant proliferation of cells that comprise the lumen of the small.

Inclusion characteristics of a) previously diagnosed and b) newly diagnosed pulmonary arterial hypertension (PAH) patients enrolled in REVEAL. PVR: pulmonary.

Representative photomicrograph of small airways abnormalities in a subject with chronic obstructive pulmonary disease. Representative photomicrograph of.

Computed tomography coronary angiogram from a 43-year-old female patient with pulmonary arterial hypertension, showing compression of the left coronary.

Electromagnetic navigation image: the icon representing the locatable guide (arrow) can be seen 3 mm away from the centre of a small pulmonary nodule in.

Diagnostic applications of metabolic dysregulation in pulmonary hypertension. Diagnostic applications of metabolic dysregulation in pulmonary hypertension.

Risk assessment and treat-to-target approach for pulmonary arterial hypertension. Risk assessment and treat-to-target approach for pulmonary arterial hypertension.

Reverse remodelling of left and right cavities under specific therapy in a patient with severe idiopathic pulmonary arterial hypertension. a) Before specific.

Difference of oxygen uptake efficiency (OUE; oxygen uptake (V′O2)/minute ventilation (V′E)) plateau between a typical pulmonary arterial hypertension (PAH)

Diagnostic imaging of distal chronic thromboembolic pulmonary hypertension lesions. a) Ventilation/perfusion scintigraphy. b) Conventional pulmonary angiography.

3-year survival of lung cancer patients in the general population and in those with a prior diagnosis of chronic obstructive pulmonary disease (COPD).

Proposed screening algorithm for identification of pulmonary arterial hypertension (PAH) associated with connective tissue disease. Proposed screening.

Evaluation of cognitive performance based on the ability to copy a simple drawing. Evaluation of cognitive performance based on the ability to copy a simple.

A summary of the pathogenesis, pathophysiology and clinical implications of the pulmonary vascular and cardiac abnormalities in interstitial lung disease.

Cumulative count of the different primary pulmonary function test (PFT) outcomes in longitudinal studies of systemic sclerosis-associated interstitial.

Simplified diagram of the multidisciplinary process to diagnose interstitial lung disease, including a clinician, radiologist, pathologist and also a geneticist:

Kaplan–Meier curves for the probability of a first adjudicated primary end-point event in the AMBITION trial, suggesting that the primary outcome events.

Survival in patients with pulmonary arterial hypertension based on aetiology. •: congenital heart disease; ▪: collagen vascular disease; ▵: HIV-related;

Right ventricular (RV) pressure–volume loops at decreasing venous return in a patient with a) systemic sclerosis-associated pulmonary arterial hypertension.

Model for the association between pathological features, physiological alterations and their association with pathological and clinical features. Model.

Proportion of patients in each World Health Organization functional class (WHO-FC) at the time of pulmonary arterial hypertension-associated systemic sclerosis.

Pulmonary angiography in the right lung (a, c, e and g) and the left lung (b, d, f and h) of a patient with chronic thromboembolic pulmonary hypertension.

The minute ventilation (V′E)/carbon dioxide production (V′CO2) relationship slope in a patient with pulmonary arterial hypertension and preserved physiological.

Prevalence of pulmonary arterial hypertension (PAH) in patients with congenital heart disease (CHD) according to defect. Prevalence of pulmonary arterial.

Pulmonary arterial hypertension specific medication use at enrolment among previously diagnosed patients. 184 (7%) of patients were not on a prostaglandin,

Morbidity and mortality benefits with statin use in observational studies on a logarithmic scale. Morbidity and mortality benefits with statin use in observational.

Distribution of mutations in sporadic and familial pulmonary arterial hypertension (PAH) and pulmonary veno-occlusive disease and/or pulmonary capillary.

Forest plot of the a) sensitivity and b) specificity of different pulmonary function test screening algorithms for the presence of systemic sclerosis-associated.

Cardiac magnetic resonance imaging of the heart in a patient with pulmonary arterial hypertension. a) Short axis image. #: dilated right ventricle; ¶:

Results of classification and regression tree analysis in patients with pulmonary hypertension-sickle cell disease. Results of classification and regression.

Survival of idiopathic pulmonary arterial hypertension (IPAH) patients in World Health Organization functional class (FC) at baseline IV is extremely poor.

Definition of pulmonary hypertension (PH) associated with left heart disease. mPAP: mean pulmonary arterial pressure; PAWP: pulmonary artery wedge pressure;

Laplace's law: T = (P×r)/2h.

A) Small pulmonary arteries within a fibrotic area (usual interstitial pneumonia lung). a) Small pulmonary arteries within a fibrotic area (usual interstitial.

A) Conventional pulmonary angiogram, with b) and c) corresponding optical coherence tomography images from a patient with chronic thromboembolic pulmonary.

Mean pulmonary arterial pressure (Ppa) as a function of cardiac output (Q) at two different levels of pulmonary vascular resistance (PVR). Mean pulmonary.

Effect of pulmonary arterial hypertension (PAH) on SF-36-measured health-related quality of life (HRQoL) measures versus the normal population and other.

A) Pulmonary arterial hypertension (PAH) aetiological breakdown of REVEAL patients at enrolment. b) Breakdown of associated PAH subgroup. a) Pulmonary.

Comorbidities/associated conditions/complications assessed in patients diagnosed with idiopathic pulmonary fibrosis (IPF) in the 2013 Advancing IPF Research.

A) Annual diagnosed incidence of pulmonary embolism (PE), and b) annual full incidence of chronic thromboembolic pulmonary hypertension (CTEPH) per 100 000.

Cardiac index (CI) changes from baseline following single oral doses of riociguat (○) 1 mg and 2.5 mg compared with inhaled nitric oxide (•) in patients.

Distribution of systolic pulmonary artery pressure (Ppa) in relation to functional class (FC) for congenital heart disease patients with a) atrial septal.

Schematic diagram of the shared subgroups between asthma and chronic obstructive pulmonary disease (COPD). Schematic diagram of the shared subgroups between.

Forest plot from meta-analysis carried out on four studies including high-dose N-acetylcysteine (NAC) treatment a) assessing the relative risk of chronic.

Correlation between inspiratory capacity (IC)/total lung capacity (TLC) ratio and oxygen pulse at peak exercise in chronic obstructive pulmonary disease.

Survival rates in older (>65 years) compared with younger (18–65 years) patients with idiopathic pulmonary arterial hypertension. a) Expected ( )

Effect of pulmonary arterial hypertension-specific treatment on systemic inflammation. a) Kaplan–Meyer survival curves for patients normalising their C-reactive.

Diagnostic algorithm for chronic thromboembolic pulmonary hypertension

Module 2: evaluation of the REVEAL risk score in the FPHN validation cohort. Module 2: evaluation of the REVEAL risk score in the FPHN validation cohort.

Reduction in mean pulmonary vascular resistance (PVR) in 37 subjects following acute sildenafil administration to ongoing bosentan therapy in the COMPASS-1.

Distribution and change of the underlying disease in patients discharged with home mechanical ventilation (n = 854). ♦: chronic obstructive pulmonary disease;

Pathogenic concepts of pulmonary arterial hypertension (PAH).

Pulmonary artery pressure in a) healthy subjects and b) pulmonary hypertension (PH) subjects. Pulmonary artery pressure in a) healthy subjects and b) pulmonary.

Mean change from baseline in percentage predicted forced vital capacity (FVC) in the a) phase III CAPACITY [27] and b) ASCEND [14] studies. #: n=174; ¶:

A) Mean pulmonary arterial pressure (Ppa) as a function of cardiac output (Q) at constant left atrial pressure (Pla) and b) Ppa as a function of Pla at.

Baseline New York Heart Association functional class (NYHA FC) predicts survival in patients with pulmonary hypertension using infused epoprostenol therapy.

Pulmonary arterial imaging before and after percutaneous balloon pulmonary angioplasty (BPA). a) Pre-procedure pulmonary angiogram demonstrating an intra-arterial.

Real-life pulmonary arterial hypertension (PAH) patient cases to reflect the importance of a collaborative approach to patient engagement. Real-life pulmonary.

High-resolution computed tomography images of smoking-related interstitial lung diseases (ILDs). a) Pulmonary Langerhans cell histiocytosis, b) respiratory.

Cardiac index (CI) changes from baseline following single oral doses of riociguat (Rio) compared with inhaled nitric oxide (NO) in patients with chronic.

Effect of placebo (n=88) and bosentan (n=80) on the co-primary end-point pulmonary vascular resistance (PVR) in the EARLY (Endothelial Antagonist Trial.

The natural history of chronic obstructive pulmonary disease (COPD) is a mixture of the natural history of the various phenotypes making up the umbrella.

Presentation transcript:

The “hallmarks of cancer” proposed by Hanahan and Weinberg [20, 21] The “hallmarks of cancer” proposed by Hanahan and Weinberg [20, 21]. a) The six hallmark capabilities originally proposed in 2000 together with the four additional hallmarks proposed in 2011. b) Although pulmonary arterial hypertension (PAH) shares several ... The “hallmarks of cancer” proposed by Hanahan and Weinberg [20, 21]. a) The six hallmark capabilities originally proposed in 2000 together with the four additional hallmarks proposed in 2011. b) Although pulmonary arterial hypertension (PAH) shares several cancer capabilities, the degree of similarity varies. Furthermore, these capabilities can be markedly different to those observed in cancer; in particular, neither invasion nor metastasis has been observed in PAH. In addition, these features found in PAH also appear to contribute to the disease pathogenesis with different levels of importance. Christophe Guignabert et al. Eur Respir Rev 2013;22:543-551 ©2013 by European Respiratory Society